One Kendall Square, Building 1400 West
Cambridge, MA 02139
Microbia Inc.
Listen to this article
Microbia Inc. has amassed a large patent portfolio covering novel targets for rendering fungi harmless, disrupting communities of bacteria, and for harnessing these organisms to the task of manufacturing useful products. Well-armed with $59 million in funding and the chemistry skills to turn biological insights into weapons against infectious diseases, Microbia hopes to create new antimicrobial drugs that work in fundamentally different ways than the drugs that are available today.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
• By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains